A Cohort Study of the Effectiveness of Trastuzumab Deruxtecan for Treating Metastatic Progressive HER2-Positive Breast Cancer
Clinical Breast Cancer · 2026-08 · 26 (8) · 7-13
DOI: 10.1016/j.clbc.2026.06.003 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Breast Cancer, 2026-08. Verfasst von Ameer Basta und 14 weiteren Autor:innen. Beteiligte Einrichtung: USF Health Morsani College of Medicine, Tampa, FL. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Trastuzumab, Immunoconjugates. Die Arbeit nennt 31 Literaturangaben. Gefördert von: H Lee Moffitt Cancer Center and Research Institute, University of South Florida.
Abstract (Originalsprache)
INTRODUCTION: The FDA approved trastuzumab deruxtecan (T-DXd) for treating human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC) based on the phase II trial DESTINY-Breast01. The phase III trial DESTINY-Breast03 confirmed the efficacy of T-DXd with improvements in progression-free survival (PFS) (HR = 0.33) and overall survival (OS) (HR = 0.64) compared with trastuzumab emtansine (T-DM1). PATIENTS AND METHODS: This is a retrospective, single-institution, effectiveness study of patients with HER2+ mBC treated with T-DXd. Data were summarized on de-identified patients, tumors, and outcomes per treating physician. The Kaplan-Meier method was used for survival analyses. A 2-sided P value .1 to obtain the final model. RESULTS: Eighty-four patients with progressive HER2+ mBC with a median age of 57 years (27-78 years) were treated with T-DXd. Of the total patients, 16.7% had an ECOG Performance Status ≥2, and 69.0% had 1 or 2 prior lines of therapy for mBC. Almost half (45.2%) had received prior T-DM1, and only 69.0% started T-DXd at full dose. Median real-world PFS (rwPFS) was 13.3 months (95% CI, 11.4-16.9). No significant differences in rwPFS were observed in stratified analyses. Median real-world OS (rwOS) was 38.7 months (95% CI, 24.5-61.8). CONCLUSION: T-DXd showed effectiveness for treating HER2+ mBC in a real-world cohort with pretreated patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- USF Health Morsani College of Medicine, Tampa, FL.
- Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
- Department of Pharmacy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
- Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Electronic address: ricardo.costa@moffitt.org.
Förderung
- H Lee Moffitt Cancer Center and Research Institute
- University of South Florida
Zitieren
APA
Basta, A., Lien, K., Ni, G., Sun, W., Whiting, J., Armitage, M., Soyano, A. E., Armaghani, A., Loftus, L., O'Connor, T., Dvir, K., Han, H. S., Soliman, H., Czerniecki, B. J., & Costa, R. L. B. (2026). A Cohort Study of the Effectiveness of Trastuzumab Deruxtecan for Treating Metastatic Progressive HER2-Positive Breast Cancer. Clinical Breast Cancer, 26(8), 7-13. https://doi.org/10.1016/j.clbc.2026.06.003
Vancouver
Basta A, Lien K, Ni G, Sun W, Whiting J, Armitage M, et al. A Cohort Study of the Effectiveness of Trastuzumab Deruxtecan for Treating Metastatic Progressive HER2-Positive Breast Cancer. Clinical Breast Cancer. 2026;26(8):7-13. doi:10.1016/j.clbc.2026.06.003
BibTeX
@article{Basta2026,
author = {Basta, Ameer and Lien, Kyle and Ni, Gabris and Sun, Weihong and Whiting, Junmin and Armitage, Melissa and Soyano, Aixa E and Armaghani, Avan and Loftus, Loretta and O'Connor, Tracey and Dvir, Kathrin and Han, Hyo S and Soliman, Hatem and Czerniecki, Brian J and Costa, Ricardo L B},
title = {A Cohort Study of the Effectiveness of Trastuzumab Deruxtecan for Treating Metastatic Progressive HER2-Positive Breast Cancer},
journal = {Clinical Breast Cancer},
year = {2026},
volume = {26},
number = {8},
pages = {7--13},
doi = {10.1016/j.clbc.2026.06.003}
}
EUVIMED